Precigen Reports Staggering $429.6M Net Loss for 2025, Operating Loss Hits $110.5M
summarizeSummary
Precigen reported a substantial net loss of $429.6 million to common shareholders for the full year 2025, alongside an operating loss of $110.5 million on total revenues of $9.7 million. This comprehensive financial disclosure, stemming from an 8-K filing, provides critical details that were not fully captured in a prior news report that focused on specific product revenue. The magnitude of the net loss, which is a significant portion of the company's market capitalization, indicates considerable financial challenges and is highly material for investors. Traders will be closely monitoring the company's cash burn and its path to achieving cash flow break-even, as stated in the article, given these substantial losses.
At the time of this announcement, PGEN was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.11 to $5.47. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.